Juno Therapeutics Inc. (JUNO)

86.96
0.09 0.10
Prev Close 86.87
Open 86.97
Day Low/High 86.90 / 87.01
52 Wk Low/High 19.62 / 87.01
Volume 3.70M
Avg Volume 4.51M
Exchange
Shares Outstanding 116.11M
Market Cap 10.10B
EPS -4.10
Div & Yield N.A. (N.A)

Bit of a Bounce Brings Sigh of Relief

Uncertainty on Greece prevails, but it could have been worse.

Stocks End Higher on Hopes Greece Could Delay Rate Hike

Stocks End Higher on Hopes Greece Could Delay Rate Hike

Stock closed higher as investors bet the Federal Reserve will delay its looming rate hike as Greece flirts with default.

Stocks Rally on Hopes Greek Crisis Will Delay Rate Hike

Stocks Rally on Hopes Greek Crisis Will Delay Rate Hike

Stocks staged a comeback as investors bet the Federal Reserve will delay its looming rate hike as Greece moves closer to default.

Stocks Pare Gains on Worries About Greek Default

Stocks Pare Gains on Worries About Greek Default

Stocks give up some of their gains on Tuesday, as a default on Greece's debt payment due to the International Monetary Fund looks unavoidable.

June 30 Premarket Briefing: 10 Things You Should Know

June 30 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are rising in the face of a potential Greek debt default. Today investors will be wrestling with uncertainty over Greece's -- and Europe's -- future.

Juno Stock Spikes on 10-Year $1 Billion Drug Development Deal With Celgene

Juno Stock Spikes on 10-Year $1 Billion Drug Development Deal With Celgene

Juno shares are rising after the company signed a 10 year $1 billion drug development deal with Celgene (CELG).

Stock Futures Rise as Greece Edges Closer to Default

Stock Futures Rise as Greece Edges Closer to Default

U.S. stock futures trade higher Tuesday as investors cling to hope that a last-minute deal will be made between Greece and its creditors.

This Is Still a Time for Selling, Not Buying in the Stock Market

I wonder why skepticism disappears so quickly these days.

Tuesday Better Have a Horrendous Opening

Remember: This is about Europe, not us.

Celgene is Desperate or Insane to Pay Ultra-High Premium for Juno Partnership

Celgene is Desperate or Insane to Pay Ultra-High Premium for Juno Partnership

Under terms of the 10-year collaboration, Celgene is buying 9.1 million shares of Juno at $93 per share -- a 102% premium to Juno's closing price of $46.30.

Market Wrap: Greece News Is Bad for Stocks

Major averages take a hit as VIX jumps.

It's Getting Awfully Choppy Up in Here

But look for another rally before the month ends.

'Mad Money' Lightning Round: Buy, Buy, Buy Citigroup

'Mad Money' Lightning Round: Buy, Buy, Buy Citigroup

Cramer says he wouldn't mind owning Caterpillar, is waiting on Alcoa and is sticking with Cypress Semiconductor.

Jim Cramer's 'Mad Money' Recap: Here's Why We Had a Rally Today

Jim Cramer's 'Mad Money' Recap: Here's Why We Had a Rally Today

The Federal Reserve statement, Greece, selling the dollar and investor confidence all had a hand, Cramer says.

Juno Therapeutics (JUNO) Stock Rising After Coverage Initiation

Juno Therapeutics (JUNO) Stock Rising After Coverage Initiation

Juno Therapeutics (JUNO) stock is gaining this morning after the company had coverage started with a 'buy' at Maxim.

4 High-Volatility Stocks to Watch for Breakouts

4 High-Volatility Stocks to Watch for Breakouts

Two biotechs and two China-based Internet companies highlight our stocks to watch today, as they carry strong technical momentum.

Juno Therapeutics (JUNO) is the ‘Chart of the Day’

Juno Therapeutics (JUNO) is the ‘Chart of the Day’

Juno Therapeutics (JUNO) is the 'Chart of the Day.'

Juno Is Reaching for the Top Again

Juno Is Reaching for the Top Again

Juno Therapeutics' stock shows a very strong uptrend and Relative Strength.

Chart of the Day: JUNO

Juno Therapeutics' stock shows a very strong uptrend and Relative Strength.

Biotech Stock Mailbag: More Duchenne Drama, CAR-T Trouble, ASCO '15 Rewind

Biotech Stock Mailbag: More Duchenne Drama, CAR-T Trouble, ASCO '15 Rewind

Biotech columnist Adam Feuerstein answers readers' questions about health care.

'Mad Money' Lightning Round: Buy, Buy, Buy Juno Therapeutics

'Mad Money' Lightning Round: Buy, Buy, Buy Juno Therapeutics

Cramer likes Blackstone's yield but says Karyopharm Therapeutics is speculative.

Jim Cramer's 'Mad Money' Recap: Individual Stocks Beat Baskets Any Day

Jim Cramer's 'Mad Money' Recap: Individual Stocks Beat Baskets Any Day

Buy what you know and pay attention, Cramer says.

Delta Lags Markets on Forex; Boeing Soars on 737 Production

Delta Lags Markets on Forex; Boeing Soars on 737 Production

Delta Air Lines (DAL) lagged the S&P 500 Tuesday after reporting a steep decline in passenger unit revenue in May.

Stocks Slip on Greece Worries, Bond Yields Hit Two-Week Highs

Stocks Slip on Greece Worries, Bond Yields Hit Two-Week Highs

The market pulled back after a rally in crude oil was overshadowed by uncertainty over Greece and surging bond yields triggered a selloff among utilities.

Stocks Are Narrowly Mixed as Oil Closes at 2015 High

Stocks Are Narrowly Mixed as Oil Closes at 2015 High

Stocks are narrowly mixed during the final hour of trading Tuesday as earlier upward momentum fades.

Juno Therapeutics (JUNO) Stock Spikes on AstraZeneca Merger Interest

Juno Therapeutics (JUNO) Stock Spikes on AstraZeneca Merger Interest

Juno Therapeutics (JUNO) shares jumped following reports that AstraZeneca might be interested in a company like Juno.